智通财经APP讯，先瑞达医疗-B(06669)公布，于2025年1月20日，集团收到中国国家药品监督管理局对冠状动脉微导管Vericor-S2®的注册批准。该产品适用于冠脉血管经皮介入手术中，针对狭窄血管病变部位，引导导丝穿通病变，为更换导丝和传输生理盐水或造影剂提供通道。冠状动脉微导管Vericor-S2®具有卓越的通过性，跟随性与推送性，能够帮助其在狭窄病变、迂曲与细小血管中穿行无阻。公司将适时在中国开展营销活动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.